Purine metabolism in patients with gout: the role of lead.
Primary gout is characterized by increased plasma and decreased urinary concentrations of hypoxanthine, xanthine and uric acid. To examine whether lead could explain the disturbance of purine metabolism in gout, we determined hypoxanthine, xanthine and uric acid metabolism and 5-day cumulative urinary lead excretion rates after an EDTA (calcium disodium edetate) test in 27 patients with primary gout and reduced creatinine clearance (C(cr)) and in 50 patients with gout and normal C(cr). The results were compared to those obtained in 26 normal subjects matched for age. All gout patients evidenced a marked renal underexcretion of hypoxanthine, xanthine and uric acid relative to their increased plasma levels. Purine metabolism was remarkably similar in both gout groups except for a significantly lower uric acid excretion in patients with reduced C(cr). Blood lead levels and cumulative lead excretion rates were significantly higher in gout patients with renal failure as compared to patients with normal C(cr). Fourteen patients (52%) with renal insufficiency and 6 (12%) with normal C(cr) showed increased lead excretion rates (95% Cl for the difference, 29-51%, p < 0.001). Mobilizable lead was not significantly correlated with serum or urinary purine concentrations. Hypoxanthine, xanthine and uric acid underexcretion was similar in gout patients with increased or normal cumulative lead excretion rates. The prevalence of atheromatosis and arterial hypertension together was significantly higher in gout patients with renal failure than in patients with normal C(cr) (81 vs. 60%, 95% Cl for the difference, 11-31%, p < 0.005). These results indicate that lead is not a significant contributor to the renal underexcretion of purines in gout. An increased mobilizable lead is not by itself evidence that lead is the cause of the renal insufficiency in patients with primary gout. Atheromatous nephropathy and/or nephroangiosclerosis may explain impaired renal function in patients with primary gout.
Miranda-Carús
E
E
Division of Internal Medicine, Universidad Autónoma, Madrid, Spain.
Mateos
F A
FA
Sanz
A G
AG
Herrero
E
E
Ramos
T
T
Puig
J G
JG
D000368:Aged; D001161:Arteriosclerosis / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood / Q000652:urine; D004492:Edetic Acid / Q000627:therapeutic use; D005260:Female; D006073:Gout / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D019271:Hypoxanthine / Q000097:blood / Q000652:urine; D007676:Kidney Failure, Chronic / Q000378:metabolism; D007854:Lead / Q000097:blood / Q000378:metabolism* / Q000652:urine; D008297:Male; D008875:Middle Aged; D011687:Purines / Q000097:blood / Q000378:metabolism* / Q000652:urine; D014527:Uric Acid / Q000097:blood / Q000652:urine
D002614:Chelating Agents; D011687:Purines; D014527:Uric Acid; D007854:Lead; D019271:Hypoxanthine; D004492:Edetic Acid; D003404:Creatinine